Search

everythinglearnresearchcommunity

for

Search:↓

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The post is an update on the user's hair loss journey. They have a strong hair follicle that has remained unaffected by hair loss for almost 3 years. The user is starting finasteride and using ketoconazole, alfatradiol, and oral castor oil for hair maintenance.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

The conversation discusses the use of RU58841 for hair loss, with one user sharing a one-month difference in their hair after using it. Users discuss where to buy RU58841, potential side effects including heart issues, and mixed opinions on its effectiveness, with some questioning the need for treatment based on the before and after pictures.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

A user shared a vlog about their experience using 5mg of pyrilutamide daily for hair loss, including before and after pictures.

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.

The user "Top_Replacement_7777" shared their positive results with finasteride for hair loss. They asked about maintaining their hair with finasteride and the impact of vaping on hair growth. Another user reassured them that vaping wouldn't affect their progress.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

The user received hormone test results showing normal estradiol and testosterone levels, low SHBG, and normal free androgen index. They are considering starting finasteride but are concerned due to being slightly overweight.

A 34-year-old underwent a hair transplant with 5,250 grafts, stem cell therapy, and PRP at Dr. Hakan Clinic in Istanbul, without using Minoxidil or Finasteride. Despite initial concerns about the hairline design, the user is optimistic about the results and plans to update progress over time.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

The conversation discusses using topical liposomal finasteride for hair loss, with concerns about high DHT levels. The user's DHT level is above the normal range, which may affect hair health.

Elevated liver enzymes were reported from taking finasteride and minoxidil. The doctor advised stopping oral minoxidil and taking finasteride every other day.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.

A user shared their positive experience with a hair transplant of 3500 grafts, showing significant improvement in appearance after 5 months. They underwent the procedure at Heva Clinic in Istanbul for $2,300 USD, which included aftercare, and attributed their hair loss to both genetics and traction alopecia from tight hairstyles.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.

After jaw surgery caused intense hair shedding and scalp itch, using pyrilutamide significantly reduced these symptoms. It's suggested to test pyrilutamide for authenticity before use, despite positive personal experience with the product from MV Supplements.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.

RU58841 is effective for long-term hair loss treatment, often used with finasteride or dutasteride for better results. Users report varying experiences with side effects and effectiveness, with some noting improvements and others experiencing shedding or needing to adjust dosages.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.